Survival Benefit For Hypotension Shock Drug Nice But Not Needed By FDA, La Jolla Says
La Jolla Pharmaceutical's angiotensin II drug LJPC-501 is on track for NDA via SPA this year, after meeting blood pressure increase primary endpoint in ATHOS-3, but also showing a trend toward an overall survival benefit.
